Enobosarm is more likely to be effective in hormone receptor positive breast cancers as a trial analyzing its utilization in triple negative breast cancer was terminated due to lack of efficacy (ClinicalTrials.gov Identifier: NCT02368691). Here, NR4A1 is linked to breast cancer.